A review of the evidence germane to the putative protective role of the macular carotenoids for age-related macular degeneration

Molecular Nutrition and Food Research

Volumn 56, Issue 2, 2012, Pages 270-286

  Sabour Pickett, Sarah ^a,b   Nolan, John M ^b,c   Loughman, James ^a,d   Beatty, Stephen ^b,c  

^a DUBLIN INSTITUTE OF TECHNOLOGY   (Ireland)

^b Ireland   (Ireland)

^c Institute of Vision Research   (Ireland)

^d University of KwaZulu Natal Faculty of Health Sciences   (South Africa)

Author keywords

Age related macular degeneration; Lutein; Macular pigment; Meso zeaxanthin; Zeaxanthin

Indexed keywords

CAROTENOID; VISUAL PIGMENT; XANTHOPHYLL; ZEAXANTHIN;

DIET SUPPLEMENTATION; DRUG EFFECT; HUMAN; METABOLISM; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA; RETINA MACULA DEGENERATION; RETINA MACULA LUTEA; REVIEW;

CAROTENOIDS; DIETARY SUPPLEMENTS; HUMANS; LUTEIN; MACULA LUTEA; MACULAR DEGENERATION; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETINA; RETINAL PIGMENTS; XANTHOPHYLLS;

EID: 84858319307     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201100219     Document Type: Review

References (171)

1. Hirsch, J., Curcio, C. A., The spatial resolution capacity of human foveal retina. Vision Res. 1989, 29, 1095-1101.
2. Attebo, K., Mitchell, P., Smith, W., Visual acuity and the causes of visual loss in Australia. The Blue Mountains Eye Study. Ophthalmology 1996, 103, 357-364.
3. Klaver, C. C., Wolfs, R. C., Vingerling, J. R., Hofman, A., de Jong, P. T., Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch. Ophthalmol. 1998, 116, 653-658.
4. Resnikoff, S., Pascolini, D., Etya'ale, D., Kocur, I. et al., Global data on visual impairment in the year 2002. Bull. World Health Organ. 2004, 82, 844-851.
5. Bressler, N. M., Age-related macular degeneration is the leading cause of blindness. J. Am. Med. Assoc. 2004, 291, 1900-1901.
6. Owen, C. G., Fletcher, A. E., Donoghue, M., Rudnicka, A. R., How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom? Br. J. Ophthalmol. 2003, 87, 312-317.
7. Kelliher, C., Kenny, D., O'Brien, C., Trends in blind registration in the adult population of the Republic of Ireland 1996-2003. Br. J. Ophthalmol. 2006, 90, 367-371.
8. Cahill, M. T., Banks, A. D., Stinnett, S. S., Toth, C. A., Vision-related quality of life in patients with bilateral severe age-related macular degeneration. Ophthalmology 2005, 112, 152-158.
9. DeCarlo, D. K., Scilley, K., Wells, J., Owsley, C., Driving habits and health-related quality of life in patients with age-related maculopathy. Optom. Vis. Sci. 2003, 80, 207-213.
10. Lamoureux, E. L., Hassell, J. B., Keeffe, J. E., The determinants of participation in activities of daily living in people with impaired vision. Am. J. Ophthalmol. 2004, 137, 265-270.
11. Hopley, C., Carter, R., Mitchell, P., Measurement of the economic impact of visual impairment from age-related macular degeneration in Australia. Clin. Exp. Ophthalmol. 2003, 31, 522-529.
12. Rein, D. B., Zhang, P., Wirth, K. E., Lee, P. P. et al., The economic burden of major adult visual disorders in the United States. Arch. Ophthalmol. 2006, 124, 1754-1760.
13. Schork, N. J., Genetics of complex disease: approaches, problems, and solutions. Am. J. Respir. Crit Care Med. 1997, 156, S103-S109.
14. Cai, J., Nelson, K. C., Wu, M., Sternberg, P., Jr., Jones, D. P., Oxidative damage and protection of the RPE. Prog. Retin. Eye Res. 2000, 19, 205-221.
15. Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S. et al., Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 2006, 355, 1419-1431.
16. Brown, D. M., Michels, M., Kaiser, P. K., Heier, J. S. et al., Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009, 116, 57-65.
17. Bressler, N. M., Chang, T. S., Suner, I. J., Fine, J. T. et al., Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology 2010, 117, 747-756.
18. Sommerburg, O., Keunen, J. E., Bird, A. C., van Kuijk, F. J., Fruits and vegetables that are sources for lutein and zeaxanthin: the macular pigment in human eyes. Br. J. Ophthalmol. 1998, 82, 907-910.
19. Maoka, T., Arai, A., Shimizu, M., Matsuno, T., The first isolation of enantiomeric and meso-zeaxanthin in nature. Comp. Biochem. Physiol B. 1986, 83, 121-124.
20. Johnson, E. J., Neuringer, M., Russell, R. M., Schalch, W., Snodderly, D. M., Nutritional manipulation of primate retinas, III: Effects of lutein or zeaxanthin supplementation on adipose tissue and retina of xanthophyll-free monkeys. Invest. Ophthalmol. Vis. Sci. 2005, 46, 692-702.
21. Bone, R. A., Landrum, J. T., Hime, G. W., Cains, A., Zamor, J., Stereochemistry of the human macular carotenoids. Invest. Ophthalmol. Vis. Sci. 1993, 34, 2033-2040.
22. Tomany, S. C., Cruickshanks, K. J., Klein, R., Klein, B. E., Knudtson, M. D., Sunlight and the 10-year incidence of age-related maculopathy: the Beaver Dam Eye Study. Arch. Ophthalmol. 2004, 122, 750-757.
23. Beatty, S., Koh, H., Phil, M., Henson, D., Boulton, M., The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv. Ophthalmol. 2000, 45, 115-134.
24. Harman, D., Aging: A theory based on free radical and radiation chemistry. J. Gerontol. 1956, 11, 298-300.
25. Harman, D., The biologic clock: the mitochondria? J. Am. Geriatr. Soc. 1972, 20, 145-147.
26. Halliwell, B., Antioxidants and human disease: a general introduction. Nutr. Rev. 1997, 55, S44-S49.
27. Sies, H., Oxidative stress: from basic research to clinical application. Am. J. Med. 1991, 91, 31S-38S.
28. Machlin, L. J., Bendich, A., Free radical tissue damage: protective role of antioxidant nutrients. FASEB J. 1987, 1, 441-445.
29. Borish, E. T., Pryor, W. A., Venugopal, S., Deutsch, W. A., DNA synthesis is blocked by cigarette tar-induced DNA single-strand breaks. Carcinogenesis 1987, 8, 1517-1520.
30. McCord, J. M., The evolution of free radicals and oxidative stress. Am. J. Med. 2000, 108, 652-659.
31. Bok, D., The retinal pigment epithelium: a versatile partner in vision. J. Cell Sci. Suppl. 1993, 17, 189-195.
32. Steinberg, R. H., Interactions between the retinal pigment epithelium and the neural retina. Doc. Ophthalmol. 1985, 60, 327-346.
33. Curcio, C. A., Medeiros, N. E., Millican, C. L., Photoreceptor loss in age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 1996, 37, 1236-1249.
34. Katz, M. L., Robison, W. G., Jr., What is lipofuscin? Defining characteristics and differentiation from other autofluorescent lysosomal storage bodies. Arch. Gerontol. Geriatr. 2002, 34, 169-184.
35. Kennedy, C. J., Rakoczy, P. E., Constable, I. J., Lipofuscin of the retinal pigment epithelium: a review. Eye (London) 1995, 9, 763-771.
36. Rozanowska, M., Jarvis-Evans, J., Korytowski, W., Boulton, M. E. et al., Blue light-induced reactivity of retinal age pigment. In vitro generation of oxygen-reactive species. J. Biol. Chem. 1995, 270, 18825-18830.
37. Sundelin, S., Wihlmark, U., Nilsson, S. E., Brunk, U. T., Lipofuscin accumulation in cultured retinal pigment epithelial cells reduces their phagocytic capacity. Curr. Eye Res. 1998, 17, 851-857.
38. Schalch, W., Carotenoids in the retina - A review of their possible role in preventing or limiting damage caused by light and oxygen. EXS 1992, 62, 280-298.
39. Ham, W. T., Jr., Mueller, H. A., Sliney, D. H., Retinal sensitivity to damage from short wavelength light. Nature 1976, 260, 153-155.
40. Pitts, D. G., A comparative study of the effects of ultraviolet radiation on the eye. Am. J. Optom. Arch. Am. Acad. Optom. 1970, 47, 535-546.
41. Algvere, P. V., Marshall, J., Seregard, S., Age-related maculopathy and the impact of blue light hazard. Acta Ophthalmol. Scand. 2006, 84, 4-15.
42. Noell, W. K., Walker, V. S., Kang, B. S., Berman, S., Retinal damage by light in rats. Invest. Ophthalmol. 1966, 5, 450-473.
43. Wu, J., Seregard, S., Algvere, P. V., Photochemical damage of the retina. Surv. Ophthalmol. 2006, 51, 461-481.
44. Ruffolo, J. J., Jr., Ham, W. T., Jr., Mueller, H. A., Millen, J. E., Photochemical lesions in the primate retina under conditions of elevated blood oxygen. Invest. Ophthalmol. Vis. Sci. 1984, 25, 893-898.
45. Boulton, M., Dontsov, A., Jarvis-Evans, J., Ostrovsky, M., Svistunenko, D., Lipofuscin is a photoinducible free radical generator. J. Photochem. Photobiol. B 1993, 19, 201-204.
46. Shaban, H., Borras, C., Vina, J., Richter, C., Phosphatidylglycerol potently protects human retinal pigment epithelial cells against apoptosis induced by A2E, a compound suspected to cause age-related macula degeneration. Exp. Eye Res. 2002, 75, 99-108.
47. Sparrow, J. R., Vollmer-Snarr, H. R., Zhou, J., Jang, Y. P. et al., A2E-epoxides damage DNA in retinal pigment epithelial cells. Vitamin E and other antioxidants inhibit A2E-epoxide formation. J. Biol. Chem. 2003, 278, 18207-18213.
48. Taylor, H. R., Munoz, B., West, S., Bressler, N. M. et al., Visible light and risk of age-related macular degeneration. Trans. Am. Ophthalmol. Soc. 1990, 88, 163-173; discussion 173-178, 163-173.
49. Wiegand, R. D., Giusto, N. M., Rapp, L. M., Anderson, R. E., Evidence for rod outer segment lipid peroxidation following constant illumination of the rat retina. Invest. Ophthalmol. Vis. Sci. 1983, 24, 1433-1435.
50. Ham, W. T., Jr., Ruffolo, J. J., Jr., Mueller, H. A., Clarke, A. M., Moon, M. E., Histologic analysis of photochemical lesions produced in rhesus retina by short-wave-length light. Invest. Ophthalmol. Vis. Sci. 1978, 17, 1029-1035.
51. Lam, S., Tso, M. O., Gurne, D. H., Amelioration of retinal photic injury in albino rats by dimethylthiourea. Arch. Ophthalmol. 1990, 108, 1751-1757.
52. Suzuki, M., Kamei, M., Itabe, H., Yoneda, K. et al., Oxidized phospholipids in the macula increase with age and in eyes with age-related macular degeneration. Mol. Vis. 2007, 13, 772-778, 772-778.
53. Lu, L., Hackett, S. F., Mincey, A., Lai, H., Campochiaro, P. A., Effects of different types of oxidative stress in RPE cells. J. Cell Physiol. 2006, 206, 119-125.
54. Seddon, J. M., Gensler, G., Milton, R. C., Klein, M. L., Rifai, N., Association between C-reactive protein and age-related macular degeneration. J. Am. Med. Assoc. 2004, 291, 704-710.
55. Donoso, L. A., Kim, D., Frost, A., Callahan, A., Hageman, G., The role of inflammation in the pathogenesis of age-related macular degeneration. Surv. Ophthalmol. 2006, 51, 137-152.
56. Ferrero-Miliani, L., Nielsen, O. H., Andersen, P. S., Girardin, S. E., Chronic inflammation: importance of NOD2 and NALP3 in interleukin-1beta generation. Clin. Exp. Immunol. 2007, 147, 227-235.
57. Johnson, L. V., Leitner, W. P., Staples, M. K., Anderson, D. H., Complement activation and inflammatory processes in Drusen formation and age related macular degeneration. Exp. Eye Res. 2001, 73, 887-896.
58. Hageman, G. S., Luthert, P. J., Victor Chong, N. H., Johnson, L. V. et al., An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog. Retin. Eye Res. 2001, 20, 705-732.
59. Anderson, D. H., Mullins, R. F., Hageman, G. S., Johnson, L. V., A role for local inflammation in the formation of drusen in the aging eye. Am. J. Ophthalmol. 2002, 134, 411-431.
60. Li, C. M., Clark, M. E., Chimento, M. F., Curcio, C. A., Apolipoprotein localization in isolated drusen and retinal apolipoprotein gene expression. Invest. Ophthalmol. Vis. Sci. 2006, 47, 3119-3128.
61. Umeda, S., Suzuki, M. T., Okamoto, H., Ono, F. et al., Molecular composition of drusen and possible involvement of anti-retinal autoimmunity in two different forms of macular degeneration in cynomolgus monkey (Macaca fascicularis). FASEB J. 2005, 19, 1683-1685.
62. Dentchev, T., Milam, A. H., Lee, V. M., Trojanowski, J. Q., Dunaief, J. L., Amyloid-beta is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas. Mol. Vis. 2003, 9, 184-190, 184-190.
63. Francis, P. J., Schultz, D. W., Hamon, S., Ott, J. et al., Haplotypes in the complement factor H (CFH) gene: associations with drusen and advanced age-related macular degeneration. PLoS One 2007, 2, e1197.
64. Doney, A. S., Leese, G. P., Olson, J., Morris, A. D., Palmer, C. N., The Y402H variant of complement factor H is associated with age-related macular degeneration but not with diabetic retinal disease in the Go-DARTS study. Diabet. Med. 2009, 26, 460-465.
65. Hollyfield, J. G., Bonilha, V. L., Rayborn, M. E., Yang, X. et al., Oxidative damage-induced inflammation initiates age-related macular degeneration. Nat. Med. 2008, 14, 194-198.
66. Klein, R., Cruickshanks, K. J., Nash, S. D., Krantz, E. M. et al., The prevalence of age-related macular degeneration and associated risk factors. Arch. Ophthalmol. 2010, 128, 750-758.
67. Smith, W., Assink, J., Klein, R., Mitchell, P. et al., Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology 2001, 108, 697-704.
68. Silvestri, G., Johnston, P. B., Hughes, A. E., Is genetic predisposition an important risk factor in age-related macular degeneration? Eye (London) 1994, 8, 564-568.
69. Klein, R., Klein, B. E., Moss, S. E., Relation of smoking to the incidence of age-related maculopathy. The Beaver Dam Eye Study. Am. J. Epidemiol. 1998, 147, 103-110.
70. Seddon, J. M., Francis, P. J., George, S., Schultz, D. W. et al., Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration. J. Am. Med. Assoc. 2007, 297, 1793-1800.
71. Mares, J. A., Voland, R. P., Sondel, S. A., Millen, A. E. et al., Healthy lifestyles related to subsequent prevalence of age-related macular degeneration. Arch. Ophthalmol. 2010.
72. SanGiovanni, J. P., Chew, E. Y., Clemons, T. E., Ferris, F. L., III et al., The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study: AREDS Report No. 22. Arch. Ophthalmol. 2007, 125, 1225-1232.
73. Nolan, J. M., Stack, J., O', D. O., Loane, E., Beatty, S., Risk factors for age-related maculopathy are associated with a relative lack of macular pigment. Exp. Eye Res. 2007, 84, 61-74.
74. Kirby, M. L., Beatty, S., Loane, E., Akkali, M. C. et al., A central dip in the macular pigment spatial profile is associated with age and smoking. Invest. Ophthalmol. Vis. Sci. 2010, 51, 6722-6728.
75. Buzzi, F., Nuove sperienze fatte sulli occhio umano 1792.
76. Soemmering, S., De foramina centrali limbo luteo cincto retinae humanae. Comment Soc. Reg. Sci. Goetting 1799, 13.
77. Home, E., An account of the orifice in the retina of the human eye, discovered by Professor Soemmering: To which are added proofs of this appearance being extended to the eyes of other animals. Philos. Trans. R. Soc. London 1798, 2, 332.
78. Nussbaum, J. J., Pruett, R. C., Delori, F. C., Historic perspectives. Macular yellow pigment. The first 200 years. Retina 1981, 1, 296-310.
79. Walls, G. L. J. H. D., The intra-ocular colour-filters of vertebrates. Br. J. Ophthalmol. 1933, 17, 641-675.
80. Schultze, M., Ueber den gelben Fleck der Retina, seinen Einfluss auf normales Sehen und auf Farbenblindheit. Cohen, 1866.
81. Chevalleraeu, A., De la colouration jaune de la macula. Ann. Oculist 1907, 241.
82. Henning, H., Optische Versuche an Vogeln und Schildkroten uber die Bedeutung der roten Oelkugeln im Auge. Arch. Gesphysiol 1920, 91-123.
83. Erhard, H., Messende Untersuchungen ueber den Farbensinn der Vogel. Zool. Jahrb. (Zool. Physiol.) 1924, 489-552.
84. Wald, G., Human vision and the spectrum. Science 1945, 101, 653-658.
85. Bone, R. A., Landrum, J. T., Tarsis, S. L., Preliminary identification of the human macular pigment. Vis. Res. 1985, 25, 1531-1535.
86. Handelman, G. J., Dratz, E. A., Reay, C. C., van Kuijk, J. G., Carotenoids in the human macula and whole retina. Invest. Ophthalmol. Vis. Sci. 1988, 29, 850-855.
87. Landrum, J. T., Bone, R. A., Moore, L. L., Gomez, C. M., Analysis of zeaxanthin distribution within individual human retinas. Methods Enzymol. 1999, 299, 457-467.
88. Neuringer, M., Sandstrom, M. M., Johnson, E. J., Snodderly, D. M., Nutritional manipulation of primate retinas, I: effects of lutein or zeaxanthin supplements on serum and macular pigment in xanthophyll-free rhesus monkeys. Invest. Ophthalmol. Vis. Sci. 2004, 45, 3234-3243.
89. Bone, R. A., Landrum, J. T., Friedes, L. M., Gomez, C. M. et al., Distribution of lutein and zeaxanthin stereoisomers in the human retina. Exp. Eye Res. 1997, 64, 211-218.
90. Whitehead, A. J., Mares, J. A., Danis, R. P., Macular pigment: A review of current knowledge. Arch. Ophthalmol. 2006, 124, 1038-1045.
91. Sujak, A., Gabrielska, J., Grudzinski, W., Borc, R. et al., Lutein and zeaxanthin as protectors of lipid membranes against oxidative damage: the structural aspects. Arch. Biochem. Biophys. 1999, 371, 301-307.
92. Landrum, J. T., Bone, R. A., Lutein, zeaxanthin, and the macular pigment. Arch. Biochem. Biophys. 2001, 385, 28-40.
93. Billsten, H. H., Bhosale, P., Yemelyanov, A., Bernstein, P. S., Polivka, T., Photophysical properties of xanthophylls in carotenoproteins from human retinas. Photochem. Photobiol. 2003, 78, 138-145.
94. Fletcher, A. E., Bentham, G. C., Agnew, M., Young, I. S. et al., Sunlight exposure, antioxidants, and age-related macular degeneration. Arch. Ophthalmol. 2008, 126, 1396-1403.
95. Barker, F. M., Snodderly, D. M., Johnson, E. J., Schalch, W. et al., Nutritional manipulation of primate retinas. V: Effects of lutein, zeaxanthin and n-3 fatty acids on retinal sensitivity to blue light damage. Invest. Ophthalmol. Vis. Sci. 2011.
96. Sundelin, S. P., Nilsson, S. E., Lipofuscin-formation in retinal pigment epithelial cells is reduced by antioxidants. Free Radic. Biol. Med. 2001, 31, 217-225.
97. Trevithick-Sutton, C. C., Foote, C. S., Collins, M., Trevithick, J. R., The retinal carotenoids zeaxanthin and lutein scavenge superoxide and hydroxyl radicals: a chemiluminescence and ESR study. Mol. Vis. 2006, 12, 1127-1135, 1127-1135.
98. Kirschfeld, K., Carotenoid pigments: Their possible role in protecting against photooxidation in eyes and photoreceptor cells. Proc. R. Soc. London B Biol. Sci. 1982, 216, 71-85.
99. Khachik, F., Bernstein, P. S., Garland, D. L., Identification of lutein and zeaxanthin oxidation products in human and monkey retinas. Invest. Ophthalmol. Vis. Sci. 1997, 38, 1802-1811.
100. Jorgensen, K., Skibsted, L. H., Carotenoid scavenging of radicals. Effect of carotenoid structure and oxygen partial pressure on antioxidative activity. Z. Lebensm. Unters. Forsch. 1993, 196, 423-429.
101. Snodderly, D. M., Auran, J. D., Delori, F. C., The macular pigment. II. Spatial distribution in primate retinas. Invest. Ophthalmol. Vis. Sci. 1984, 25, 674-685.
102. Trieschmann, M., van Kuijk, F. J., Alexander, R., Hermans, P. et al., Macular pigment in the human retina: histological evaluation of localization and distribution. Eye (London) 2008, 22, 132-137.
103. Beatty, S., Boulton, M., Henson, D., Koh, H. H., Murray, I. J., Macular pigment and age related macular degeneration. Br. J. Ophthalmol. 1999, 83, 867-877.
104. Wrona, M., Rozanowska, M., Sarna, T., Zeaxanthin in combination with ascorbic acid or alpha-tocopherol protects ARPE-19 cells against photosensitized peroxidation of lipids. Free Radic. Biol. Med. 2004, 36, 1094-1101.
105. Siems, W. G., Sommerburg, O., van Kuijk, F. J., Lycopene and beta-carotene decompose more rapidly than lutein and zeaxanthin upon exposure to various pro-oxidants in vitro. Biofactors 1999, 10, 105-113.
106. Cantrell, A., McGarvey, D. J., Truscott, T. G., Rancan, F., Bohm, F., Singlet oxygen quenching by dietary carotenoids in a model membrane environment. Arch. Biochem. Biophys. 2003, 412, 47-54.
107. Bhosale, P., Bernstein, P. S., Synergistic effects of zeaxanthin and its binding protein in the prevention of lipid membrane oxidation. Biochim. Biophys. Acta. 2005, 1740, 116-121.
108. Thomson, L. R., Toyoda, Y., Langner, A., Delori, F. C. et al., Elevated retinal zeaxanthin and prevention of light-induced photoreceptor cell death in quail. Invest. Ophthalmol Vis. Sci. 2002, 43, 3538-3549.
109. Chucair, A. J., Rotstein, N. P., SanGiovanni, J. P., During, A. et al., Lutein and zeaxanthin protect photoreceptors from apoptosis induced by oxidative stress: relation with docosahexaenoic acid. Invest. Ophthalmol Vis. Sci. 2007, 48, 5168-5177.
110. Li, B., Ahmed, F., Bernstein, P. S., Studies on the singlet oxygen scavenging mechanism of human macular pigment. Arch. Biochem. Biophys. 2010, 504, 56-60.
111. Nebeling, L. C., Forman, M. R., Graubard, B. I., Snyder, R. A., The impact of lifestyle characteristics on carotenoid intake in the United States: the 1987 National Health Interview Survey. Am. J. Public Health. 1997, 87, 268-271.
112. Perry, A., Rasmussen, H., Johnson, E., Xanthophyll (lutein, zeaxanthin) content in fruits, vegetables and corn and egg products. J. Food Comp. Anal. 2009, 22, 9-15.
113. Chung, H. Y., Rasmussen, H. M., Johnson, E. J., Lutein bioavailability is higher from lutein-enriched eggs than from supplements and spinach in men. J. Nutr. 2004, 134, 1887-1893.
114. Thurnham, D. I., Macular zeaxanthins and lutein - a review of dietary sources and bioavailability and some relationships with macular pigment optical density and age-related macular disease. Nutr. Res. Rev. 2007, 20, 163-179.
115. Connolly, E. E., Beatty, S., Thurnham, D. I., Loughman, J. et al., Augmentation of macular pigment following supplementation with all three macular carotenoids: an exploratory study. Curr. Eye Res. 2010, 35, 335-351.
116. Harbour, R., Miller, J., A new system for grading recommendations in evidence based guidelines. BMJ 2001, 323, 334-336.
117. Sackett, D. L., The Cochrane Collaboration. ACP J. Club. 1994, 120, A11., A11.
118. Black, N., Why we need observational studies to evaluate the effectiveness of health care. BMJ 1996, 312, 1215-1218.
119. Stephenson, J., Imrie, J., Why do we need randomised controlled trials to assess behavioural interventions? BMJ 1998, 316, 611-613.
120. Hennekens, C. H., Buring, J. E., Observational evidence. Ann NY Acad. Sci. 1993, 703, 18-24; discussion 24, 18-24.
121. Rychetnik, L., Frommer, M., Hawe, P., Shiell, A., Criteria for evaluating evidence on public health interventions. J. Epidemiol. Community Health. 2002, 56, 119-127.
122. Richer, S., ARMD - pilot (case series) environmental intervention data. J. Am. Optom. Assoc. 1999, 70, 24-36.
123. Olmedilla, B., Granado, F., Blanco, I., Vaquero, M., Cajigal, C., Lutein in patients with cataracts and age-related macular degeneration: a long-term supplementation study. J. Sci. Food Agric. 2001, 81, 904-909.
124. Bartlett, H. E., Eperjesi, F., Effect of lutein and antioxidant dietary supplementation on contrast sensitivity in age-related macular disease: a randomized controlled trial. Eur. J. Clin. Nutr. 2007, 61, 1121-1127.
125. Richer, S., Stiles, W., Statkute, L., Pulido, J. et al., Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry 2004, 75, 216-230.
126. Chakravarthy, U., Beatty, S., Stevenson, M., The CARMA study group. Functional and Morphological Outcomes in the CARMA Clinical Trial. 2009, ARVO E-Abstract 1257.
127. Neelam, K., Hogg, R. E., Stevenson, M. R., Johnston, E. et al., Carotenoids and co-antioxidants in age-related maculopathy: design and methods. Ophthal. Epidemiol. 2008, 15, 389-401.
128. Weigert, G., Kaya, S., Pemp, B., Lasta, M. et al., Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. Invest. Opthalmol. Vis. Sci. 2011, 52, 8174-8178.
129. Jentsch, S., Schweitzer, D., Hammer, M., Lang, G. E., Dawczynski, J., The Lutega-Study: Lutein and omega- 3-fatty acids and their relevance for macular pigment in patients with age-related macular degeneration (AMD). Klin. Monbl. Augenheilkd. 2011, Epub.
130. Kearney, P. M.., Cronin, H., O'Regan, C., Kamiya, Y. et al., Cohort profile: the Irish longitudinal study on ageing. Int. J. Epidemiol. Epub. 2010, 1464-3685.
131. Nolan, J. M., Kenny, R., O'Regan, C., Cronin, H. et al., Macular pigment optical density in an ageing Irish population: The Irish longitudinal study on ageing. Ophthal. Res. 2010, 44, 131-139.
132. Seddon, J. M., Ajani, U. A., Sperduto, R. D., Hiller, R. et al., Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study Group. J. Am. Med. Assoc. 1994, 272, 1413-1420.
133. VandenLangenberg, G. M., Mares-Perlman, J. A., Klein, R., Klein, B. E. et al., Associations between antioxidant and zinc intake and the 5-year incidence of early age-related maculopathy in the Beaver Dam Eye Study. Am. J. Epidemiol. 1998, 148, 204-214.
134. Mares-Perlman, J. A., Fisher, A. I., Klein, R., Palta, M. et al., Lutein and zeaxanthin in the diet and serum and their relation to age-related maculopathy in the third national health and nutrition examination survey. Am. J. Epidemiol. 2001, 153, 424-432.
135. Flood, V., Smith, W., Wang, J. J., Manzi, F. et al., Dietary antioxidant intake and incidence of early age-related maculopathy: the Blue Mountains Eye Study. Ophthalmology 2002, 109, 2272-2278.
136. Moeller, S. M., Parekh, N., Tinker, L., Ritenbaugh, C. et al., Associations between intermediate age-related macular degeneration and lutein and zeaxanthin in the Carotenoids in Age-related Eye Disease Study (CAREDS): ancillary study of the Women's Health Initiative. Arch. Ophthalmol. 2006, 124, 1151-1162.
137. Snellen, E. L., Verbeek, A. L., Van Den Hoogen, G. W., Cruysberg, J. R., Hoyng, C. B., Neovascular age-related macular degeneration and its relationship to antioxidant intake. Acta Ophthalmol. Scand. 2002, 80, 368-371.
138. Tan, J. S., Wang, J. J., Flood, V., Rochtchina, E. et al., Dietary antioxidants and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. Ophthalmology 2008, 115, 334-341.
139. Antioxidant status and neovascular age-related macular degeneration. Eye Disease Case-Control Study Group. Arch. Ophthalmol. 1993, 111, 104-109.
140. Mares-Perlman, J. A., Brady, W. E., Klein, R., Klein, B. E. et al., Serum antioxidants and age-related macular degeneration in a population-based case-control study. Arch. Ophthalmol. 1995, 113, 1518-1523.
141. Simonelli, F., Zarrilli, F., Mazzeo, S., Verde, V. et al., Serum oxidative and antioxidant parameters in a group of Italian patients with age-related maculopathy. Clin. Chim. Acta. 2002, 320, 111-115.
142. Gale, C. R., Hall, N. F., Phillips, D. I., Martyn, C. N., Lutein and zeaxanthin status and risk of age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2003, 44, 2461-2465.
143. Cardinault, N., Abalain, J. H., Sairafi, B., Coudray, C. et al., Lycopene but not lutein nor zeaxanthin decreases in serum and lipoproteins in age-related macular degeneration patients. Clin. Chim. Acta 2005, 357, 34-42.
144. Delcourt, C., Carriere, I., Delage, M., Barberger-Gateau, P., Schalch, W., Plasma lutein and zeaxanthin and other carotenoids as modifiable risk factors for age-related maculopathy and cataract: The POLA Study. Invest. Ophthalmol. Vis. Sci. 2006, 47, 2329-2335.
145. Landrum, J. T., Bone, R. A., Joa, H., Kilburn, M. D. et al., A one year study of the macular pigment: the effect of 140 days of a lutein supplement. Exp. Eye Res. 1997, 65, 57-62.
146. Stone, W. L., Farnsworth, C. C., Dratz, E. A., A reinvestigation of the fatty acid content of bovine, rat and frog retinal rod outer segments. Exp. Eye Res. 1979, 28, 387-397.
147. Bazan, N. G., The metabolism of omega-3 polyunsaturated fatty acids in the eye: the possible role of docosahexaenoic acid and docosanoids in retinal physiology and ocular pathology. Prog. Clin. Biol. Res. 1989, 312, 95-112.
148. SanGiovanni, J. P., Chew, E. Y., The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Prog. Retin. Eye Res. 2005, 24, 87-138.
149. Hodge, W. G., Barnes, D., Schachter, H. M., Pan, Y. I. et al., Evidence for the effect of omega-3 fatty acids on progression of age-related macular degeneration: A systematic review. Retina 2007, 27, 216-221.
150. Chong, E. W., Kreis, A. J., Wong, T. Y., Simpson, J. A., Guymer, R. H., Dietary omega-3 fatty acid and fish intake in the primary prevention of age-related macular degeneration: a systematic review and meta-analysis. Arch. Ophthalmol. 2008, 126, 826-833.
151. Berendschot, T. T., Goldbohm, R. A., Klopping, W. A., van de, K. J. et al., Influence of lutein supplementation on macular pigment, assessed with two objective techniques. Invest Ophthalmol. Vis. Sci. 2000, 41, 3322-3326.
152. Johnson, E. J., Hammond, B. R., Yeum, K. J., Qin, J. et al., Relation among serum and tissue concentrations of lutein and zeaxanthin and macular pigment density. Am. J. Clin. Nutr. 2000, 71, 1555-1562.
153. Hughes, D. A., Wright, A. J., Finglas, P. M., Polley, A. C. et al., Effects of lycopene and lutein supplementation on the expression of functionally associated surface molecules on blood monocytes from healthy male nonsmokers. J. Infect. Dis. 2000, 182, S11-S15.
154. Bone, R. A., Landrum, J. T., Guerra, L. H., Ruiz, C. A., Lutein and zeaxanthin dietary supplements raise macular pigment density and serum concentrations of these carotenoids in humans. J. Nutr. 2003, 133, 992-998.
155. Koh, H. H., Murray, I. J., Nolan, D., Carden, D. et al., Plasma and macular responses to lutein supplement in subjects with and without age-related maculopathy: a pilot study. Exp. Eye Res. 2004, 79, 21-27.
156. Zhao, X., Aldini, G., Johnson, E. J., Rasmussen, H. et al., Modification of lymphocyte DNA damage by carotenoid supplementation in postmenopausal women. Am. J. Clin. Nutr. 2006, 83, 163-169.
157. Schalch, W., Cohn, W., Barker, F. M., Kopcke, W. et al., Xanthophyll accumulation in the human retina during supplementation with lutein or zeaxanthin - the LUXEA (LUtein Xanthophyll Eye Accumulation) study. Arch. Biochem. Biophys. 2007, 458, 128-135.
158. Bone, R. A., Landrum, J. T., Cao, Y., Howard, A. N., varez-Calderon, F., Macular pigment response to a supplement containing meso-zeaxanthin, lutein and zeaxanthin. Nutr. Metab. (Lond) 2007, 4, 12.
159. Wenzel, A. J., Sheehan, J. P., Gerweck, C., Stringham, J. M. et al., Macular pigment optical density at four retinal loci during 120 days of lutein supplementation. Ophthalmic. Physiol. Opt. 2007, 27, 329-335.
160. Thurnham, D. I., Tremel, A., Howard, A. N., A supplementation study in human subjects with a combination of meso-zeaxanthin, (3R, 3'R)-zeaxanthin and (3R, 3'R, 6'R)-lutein. Br. J. Nutr. 2008, 100, 1307-1314.
161. Johnson, E. J., Chung, H. Y., Caldarella, S. M., Snodderly, D. M., The influence of supplemental lutein and docosahexaenoic acid on serum, lipoproteins, and macular pigmentation. Am. J. Clin. Nutr. 2008, 87, 1521-1529.
162. Bone, R. A., Landrum, J. T., Dose-dependent response of serum lutein and macular pigment optical density to supplementation with lutein esters. Arch. Biochem. Biophys. 2010, 504, 50-55.
163. Nolan, J. M., Loughman, J., Akkali, M. C., Stack, J. et al., The impact of macular pigment augmentation on visual performance in normal subjects: COMPASS. Vision Res. 2011, 51, 459-469.
164. Khachik, F., de Moura, F. F., Chew, E. Y., Douglass, L. W. et al., The effect of lutein and zeaxanthin supplementation on metabolites of these carotenoids in the serum of persons aged 60 or older. Invest. Ophthalmol. Vis. Sci. 2006, 47, 5234-5242.
165. Trieschmann, M., Beatty, S., Nolan, J. M., Hense, H. W. et al., Changes in macular pigment optical density and serum concentrations of its constituent carotenoids following supplemental lutein and zeaxanthin: the LUNA study. Exp. Eye Res. 2007, 84, 718-728.
166. Huang, L. L., Coleman, H. R., Kim, J., de, M. F. et al., Oral supplementation of lutein/zeaxanthin and omega-3 long chain polyunsaturated fatty acids in persons aged 60 years or older, with or without AMD. Invest. Ophthalmol. Vis. Sci. 2008, 49, 3864-3869.
167. Hammond, B. R., Jr., Johnson, E. J., Russell, R. M., Krinsky, N. I. et al., Dietary modification of human macular pigment density. Invest. Ophthalmol. Vis. Sci. 1997, 38, 1795-1801.
168. Aleman, T. S., Duncan, J. L., Bieber, M. L., de, C. E. et al., Macular pigment and lutein supplementation in retinitis pigmentosa and Usher syndrome. Invest. Ophthalmol. Vis. Sci. 2001, 42, 1873-1881.
169. Bernstein, P. S., Zhao, D. Y., Sharifzadeh, M., Ermakov, I. V., Gellermann, W., Resonance Raman measurement of macular carotenoids in the living human eye. Arch. Biochem. Biophys. 2004, 430, 163-169.
170. Stringham, J. M., Hammond, B. R., Macular pigment and visual performance under glare conditions. Optom. Vis. Sci. 2008, 85, 82-88.
171. Richer, S., Devenport, J., Lang, J. C., LAST II: differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. Optometry 2007, 78, 213-219.